Press Release 05.07.24
Pillsbury Provides Strategic Advice for Sentynl Therapeutics’ Acquisition of Global Rights to Zokinvy® for Treatment of Progeria
Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022) and Japan (2024) for the treatment of progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients